The Next Management Target of ASCVD-anti-inflammatory therapy
In the past,cholesterol was believed to be a pathogenic risk factor for ASCVD.With the deepening of research,ASCVD is no longer considered a simple arterial wall lipid accumulation disease,but may be a progressive inflammatory response.This article reviews the development of coronary artery anti-inflammatory strategies,clarifies the"inflammation theory",reviews several studies on the application of low-dose colchicine in coronary heart dis-ease,and further clarifies that inflammation treatment will be the next management target of ASCVD.Managing in-flammation is of great significance in reducing cardiovascular risk events.